Clinical Trials Browser

Neuroblastoma, Recurrence

NCT01445080 2021-02-02

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT01531361 2021-01-22

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

Phase 1 Completed

46 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT01561833 2020-08-13

A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients

Phase 1 Completed

12 enrolled 4 charts

Lymphoid

Recurrence, Lymphoma, T-Cell

NCT02530476 2020-03-31

Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

Phase 1/2 Completed

17 enrolled 14 charts

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02867280 2020-02-11

Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection

Phase 3 Terminated

154 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Recurrence

NCT02187081 2017-03-28

Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCC

Phase NA Unknown

380 enrolled

Recurrence

NCT02015728 2016-12-15

SEED

Phase NA Unknown

20 enrolled

Neoplasms, Recurrence

NCT01683149 2016-03-04

Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies

Phase 1 Completed

13 enrolled

Neoplasms, Recurrence

NCT01851408 2015-04-15

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Phase 2 Withdrawn

Dermatologic

Melanoma, Recurrence

NCT00747799 2013-12-10

Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Phase 2 Completed

54 enrolled

Head & Neck

Nasopharyngeal Neoplasms, Recurrence

NCT00536575 2013-02-27

Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients

Phase 1/2 Completed

13 enrolled 5 charts

Plasma cell

Multiple Myeloma, Recurrence

NCT01262482 2012-11-09

Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment

Phase 2 Completed

41 enrolled

Adenocarcinoma, Recurrence

Clinical Trials

N2013-02

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients

Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection

Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCC

SEED

Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients

Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment